Apogee Therapeutics, Inc. (APGE) Investor Relations Documents

Apogee Therapeutics, Inc. (APGE) investor relations documents from the company's IR site: 18 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-10Press releaseApogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
2026-06-22Press releaseAbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
2026-05-28Press releaseApogee Therapeutics to Participate in Upcoming June Conferences
2026-05-27Press releaseApogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zum
2026-05-27Press releaseApogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Ph
2026-05-26Press releaseApogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in
2026-05-11Press releaseApogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
2026-03-26Press releaseApogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase
2026-03-24Press releaseApogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
2026-03-23Press releaseApogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
2026-03-23Press releaseApogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance a
2026-03-22Press releasePDF Version
2026-03-22Press releaseApogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (A
2026-02-24Press releasePDF Version
2026-02-24Press releaseApogee Therapeutics to Participate in Upcoming March Conferences
2026-02-05Press releasePDF Version
2026-02-05Press releaseApogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
2026-01-05Press releaseApogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with

APGE overview · APGE earnings · APGE financials · APGE KPIs · APGE ownership · APGE peers · APGE filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.